Hematologic Oncology

A hematologist/oncologist discusses ongoing research on targeted therapy for patients with relapsed/refractory chronic lymphocytic leukemia.

Comprehensive insights on clinical and patient factors that inform treatment selection and sequencing for patients with B-cell malignancies.

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Experts on follicular lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Fernando Cabanillas, MD, a mentor and leader in the lymphoma field, is being recognized for his contributions to the hematologic oncology space.

Dedication to his patients and the field of hematology spanning decades has led Stephen J. Forman, MD, to break down barriers for treating patients with leukemia and lymphoma.

A review of recent data regarding maintenance therapy for patients with AML who achieve first remission, including updates from the 2023 ASH Annual meeting.

Catherine E. Lai, MD, MPH, shares her approach to treatment after a patient with AML completes induction therapy.

Expert perspectives on the toxicities seen with targeted therapies in chronic lymphocytic leukemia and how they’re mitigated and managed.

An expert on hematologic malignancies discusses recent data from ASH 2023 in relapsed/refractory CLL/SLL, highlighting the ALPINE study investigating zanubrutinib versus ibrutinib.

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Fred Locke, MD shares his perspective on the future treatment paradigm in large B-cell lymphoma, emphasizing CAR-T cells, allogeneic strategies, bispecifics, toxicity management, and treatment sequencing.

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).

Insight into monitoring patients who are being treated for AML, what constitutes complete remission, and how and why it’s important to test for minimal residual disease to determine a patient’s risk for relapse.

Catherine E. Lai, MD, MPH, discusses the current standard of care in the first-line treatment of patients with AML and which factors guide therapy selection.

Expert perspectives on the role of biomarker testing in the diagnosis and management of acute myeloid leukemia.

Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.

Panelist introductions by Gregory Roloff, MD from the University of Chicago Comprehensive Cancer Center, Chicago, Illinois; Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, New York; and Bijal Shah, MD, from the Moffitt Cancer Center, Tampa, Florida.

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

Nicole Lamanna, MD, discusses the results from the ongoing BGB-11417-101 study investigating combination zanubrutinib plus sonrotoclax in patients with treatment-naïve CLL/SLL.

A hematologist/oncologist previews updated data presented at ASH 2023 for patients with B-cell malignancies.

Nicole Lamanna, MD, gives an overview of targeted therapies and the role of prognostic markers in the treatment of B-cell malignancies.

Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Guillermo Garcia-Manero, MD, presents data from the COMMANDS trial investigating luspatercept in erythropoiesis-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes.